PPCB

Quote

Short

News

Articles

Message Board

Propanc Biopharma Inc (OTCMKTS : PPCB ) News

Propanc Biopharma Inc (OTCMKTS: PPCB) News Releases

PPCB News Releases

March 03, 2026 08:45:00 am

GlobeNewswire

Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

February 18, 2026 03:42:43 pm

SeekingAlpha

Propanc Biopharma, Inc. GAAP EPS of -$0.30

February 18, 2026 08:45:00 am

GlobeNewswire

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

February 05, 2026 08:45:00 am

GlobeNewswire

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

January 29, 2026 03:31:04 pm

QM US Market Movers News

US Companies Moving the Markets, Evening edition
Thu, Jan 29, 2026 as of 4:00 pm ET

January 29, 2026 09:01:03 am

QM US Market Movers News

US Companies Moving the Markets, Morning edition
Thu, Jan 29, 2026 as of 10.00 am ET

January 27, 2026 08:45:00 am

GlobeNewswire

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months - Strengthening Global Protection for Breakthrough Proenzyme Formulations

January 20, 2026 08:45:00 am

GlobeNewswire

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia

January 15, 2026 08:45:00 am

GlobeNewswire

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

December 22, 2025 07:00:00 am

GlobeNewswire

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Subscribe to Our Newsletter

Download The Market Wire News App

Link Market Wire News to Your X Account